GlaxoSmithKline plc (GSK.L)
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
Company Info
ISIN | GB00BN7SWP63 |
---|---|
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Highlights
Market Cap | £61.02B |
---|---|
EPS (TTM) | £1.13 |
PE Ratio | 13.24 |
PEG Ratio | 0.83 |
Total Revenue (TTM) | £23.30B |
Gross Profit (TTM) | £16.94B |
EBITDA (TTM) | £7.39B |
Year Range | £1,325.32 - £1,806.38 |
Target Price | £2,128.25 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: GSK.L vs. DGE.L, GSK.L vs. SPY, GSK.L vs. AZN.L, GSK.L vs. HMWO.L, GSK.L vs. RELX, GSK.L vs. VOO, GSK.L vs. SWDA.L, GSK.L vs. EQQQ.L
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in GlaxoSmithKline plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
GlaxoSmithKline plc had a return of 6.03% year-to-date (YTD) and 3.26% in the last 12 months. Over the past 10 years, GlaxoSmithKline plc had an annualized return of 5.95%, while the S&P 500 had an annualized return of 11.99%, indicating that GlaxoSmithKline plc did not perform as well as the benchmark.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | 6.03% | 22.49% |
1 month | -8.33% | 3.72% |
6 months | -4.23% | 16.33% |
1 year | 3.26% | 33.60% |
5 years (annualized) | 2.46% | 14.41% |
10 years (annualized) | 5.95% | 11.99% |
Monthly Returns
The table below presents the monthly returns of GSK.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 8.12% | 7.19% | 2.64% | -2.08% | 6.47% | -13.42% | -1.14% | 10.63% | -8.48% | 6.03% | |||
2023 | -0.99% | 1.08% | 0.25% | 0.84% | -5.65% | 3.15% | -0.30% | 1.34% | 7.43% | -2.32% | -1.62% | 2.17% | 4.94% |
2022 | 2.27% | -4.56% | 6.59% | 9.09% | -2.82% | 1.90% | -3.13% | -19.23% | -5.34% | 9.42% | -0.54% | 2.19% | -7.42% |
2021 | 1.12% | -10.65% | 8.16% | 4.01% | 1.74% | 5.59% | -0.11% | 4.40% | -3.99% | 7.48% | 2.32% | 5.35% | 26.66% |
2020 | 0.28% | -11.23% | -3.05% | 9.67% | 1.75% | -2.11% | -6.53% | -2.64% | -1.36% | -11.03% | 7.43% | -2.04% | -20.76% |
2019 | -0.94% | 2.86% | 6.64% | -1.47% | -1.74% | 3.25% | 7.99% | 1.68% | 1.93% | 1.38% | 0.26% | 1.43% | 25.32% |
2018 | -0.16% | 0.73% | 6.64% | 4.84% | 5.63% | 0.38% | 3.39% | -0.18% | -1.51% | -1.67% | 8.62% | -8.04% | 19.02% |
2017 | -2.18% | 9.36% | 0.70% | -6.60% | 11.19% | -3.99% | -7.40% | 2.53% | -2.93% | -8.80% | -4.43% | 3.36% | -10.82% |
2016 | 4.81% | -1.37% | 0.89% | 3.33% | 0.32% | 11.04% | 5.20% | -1.81% | 0.24% | -1.49% | -6.50% | 4.45% | 19.57% |
2015 | 6.61% | 6.64% | 0.29% | -2.04% | -2.77% | -9.01% | 5.56% | -2.69% | -5.56% | 10.98% | -2.18% | 1.29% | 5.43% |
2014 | -2.95% | 8.33% | -4.79% | 2.54% | -0.76% | -2.31% | -8.15% | 4.00% | -4.17% | 0.32% | 6.15% | -7.34% | -10.11% |
2013 | 8.28% | 2.61% | 5.67% | 7.93% | 4.60% | -3.82% | 2.18% | -0.98% | -5.35% | 5.52% | -0.38% | -0.43% | 27.77% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GSK.L is 42, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
GlaxoSmithKline plc granted a 4.01% dividend yield in the last twelve months. The annual payout for that period amounted to £0.60 per share.
Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dividend | £0.60 | £0.56 | £0.67 | £0.80 | £0.80 | £0.80 | £0.80 | £0.80 | £0.77 | £0.80 | £0.80 | £0.92 |
Dividend yield | 4.01% | 3.84% | 4.66% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% | 5.76% | 5.62% |
Monthly Dividends
The table displays the monthly dividend distributions for GlaxoSmithKline plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | £0.00 | £0.16 | £0.00 | £0.00 | £0.15 | £0.00 | £0.00 | £0.15 | £0.00 | £0.00 | £0.46 | ||
2023 | £0.00 | £0.14 | £0.00 | £0.00 | £0.14 | £0.00 | £0.00 | £0.14 | £0.00 | £0.00 | £0.14 | £0.00 | £0.56 |
2022 | £0.00 | £0.23 | £0.00 | £0.00 | £0.14 | £0.00 | £0.00 | £0.16 | £0.00 | £0.00 | £0.14 | £0.00 | £0.67 |
2021 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2020 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2019 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2018 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2017 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2016 | £0.00 | £0.20 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.77 |
2015 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2014 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.00 | £0.19 | £0.00 | £0.80 |
2013 | £0.28 | £0.00 | £0.00 | £0.23 | £0.00 | £0.00 | £0.23 | £0.00 | £0.00 | £0.19 | £0.00 | £0.92 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the GlaxoSmithKline plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GlaxoSmithKline plc was 50.10%, occurring on Mar 12, 2003. Recovery took 2058 trading sessions.
The current GlaxoSmithKline plc drawdown is 15.98%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-50.1% | Jan 11, 1999 | 1053 | Mar 12, 2003 | 2058 | May 5, 2011 | 3111 |
-43.98% | Jan 14, 1992 | 395 | Aug 13, 1993 | 554 | Oct 23, 1995 | 949 |
-31.01% | Jan 20, 2020 | 282 | Feb 26, 2021 | 223 | Jan 17, 2022 | 505 |
-27.99% | Jul 5, 2022 | 56 | Sep 22, 2022 | 368 | Mar 7, 2024 | 424 |
-25.89% | Jun 23, 2017 | 159 | Feb 6, 2018 | 133 | Aug 16, 2018 | 292 |
Volatility
Volatility Chart
The current GlaxoSmithKline plc volatility is 6.35%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of GlaxoSmithKline plc compared to its peers in the Drug Manufacturers - General industry.
PE Ratio
PEG Ratio
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for GlaxoSmithKline plc.
Loading data...
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |